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Expanding the armamentarium for the treatment of 
Clostridium difficile infection
In The Lancet Infectious Diseases, Richard Vickers 
and colleagues1 report results of a phase 2 study of 
ridinilazole, a promising new drug for the treatment 
of Clostridium difficile infection. Although efforts to 
improve infection control practices and antimicrobial 
stewardship have led to significant reductions in some 
countries,2 C difficile infection remains a substantial 
problem worldwide.
All-cause 30-day mortality associated with C difficile 
infection has been reported to be in the region of 
9–38%.3,4 Furthermore, cases are associated with 
excess length of hospital stay of approximately 7 days 
(and 12 days in severe cases).3 C difficile infection usually 
occurs following disruption of the intestinal microbiota 
resulting from exposure to antibiotics. The risk of 
C difficile infection increases by up to six times during 
antibiotic therapy and in the month thereafter.5,6
Risk of disease recurrence within 8 weeks of treatment 
of an initial episode is estimated to be approximately 
15–25%; for those with more than one previous 
recurrence, the risk of further recurrences increases 
to 40–65%.7,8 Recurrences have been associated with 
impaired immune responses to C difficile toxins together 
with disturbance of the indigenous colonic microbiota. 
Continued use of antibiotics, as well as numerous other 
factors such as concomitant anti-ulcer medication and 
older age (particularly those older than 65 years) are well 
recognised risk factors for recurrence.7 Management 
of such patients is challenging and places substantial 
demand on health-care resources.
For several decades the only available drugs to treat 
C difficile infection were metronidazole and vancomycin. 
Concerns over emerging resistance and worsening 
clinical outcomes have resulted in a shift away from 
the use of metronidazole, even for non-severe cases.9,10 
Fidaxomicin was licensed in the European Union and 
USA in 2011. Its use has led to significant reductions 
in recurrences compared with the use of vancomycin, 
particularly when it is not restricted to highly selected 
cases.11 Despite its effectiveness for all C difficile 
infections, fidaxomicin is generally used to treat a 
first recurrence; this decision is probably driven by the 
greater cost of the drug compared with vancomycin. 
However, this strategy could be short-sighted since the 
costs of managing recurrent episodes can be severe.12
Because of the limited number of effective 
antimicrobials available to treat C difficile infection, the 
development of new drugs is vital. An ideal agent would 
be bactericidal against vegetative cells, inhibit spore and 
toxin production, have targeted activity against C difficile 
while sparing indigenous gut flora, be poorly absorbed 
from the gastrointestinal tract, and be well tolerated. 
Ridinilazole appears to have many of these attributes, 
making it a good candidate for further development.
The main outcome measure reported by Vickers and 
colleagues1 was sustained clinical response. This is a 
combined endpoint that measures cure at the end of 
treatment (resolution of symptoms with three or fewer 
unformed bowel movements over a 24-h period) and 
an absence of recurrence in the 30 days after treatment. 
24 (66·7%) of 36 patients in the ridinilazole group had a 
sustained clinical response compared with 14 (42·4%) of 
33 patients in the vancomycin group, showing statistical 
superiority in the modified intention-to-treat analysis. 
Subgroup analysis of this outcome measure showed 
that ridinilazole performed better than vancomycin 
in patients older than 75 years, those with markers 
of severe disease, those with one or more episodes of 
C difficile infection, and those requiring concomitant 
antibiotics, although the differences were not all 
statistically significant because of the low numbers. 
Recurrence of infection occurred in four (14·3%) of 
28 ridinilazole-treated participants versus eight (34·8%) 
of 23 vancomycin-treated participants.
The study was somewhat limited by the inclusion of 
patients who were slightly younger than those who might 
be expected to be seen in everyday clinical practice (most 
patients were younger than 65 years). Similarly, only 10% 
in the ridinilazole group and 8% in the vancomycin group 
had a previous episode of C difficile infection, and just 14% 
in the ridinilazole group and 18% in the vancomycin group 
had severe disease. Furthermore, it is unclear why some 
of the centres were not able to recruit to the study (only 
21 of 33 [64%] sites recruited patients). Discounting these 
shortcomings, it is rare for a study of an antimicrobial to 
show statistical superiority over the standard of care.
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The main advantage of ridinilazole and other new 
drugs such as fidaxomicin and bezlotoxumab appears to 
be related to the reduction or prevention of recurrence. 
Therefore, the development of bedside tools that can 
be used in real time to predict accurately the risk of 
recurrent C difficile infection could be helpful. These 
tools could help to optimise treatment for those at risk 
of severe, complicated, or recurrent infection at the early 
stages of disease and drive improvement in a range of 
clinical outcomes.
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